All In Biotech

Drug Trial Radar · NCT04972110

Study of RP-3500 (Camonsertib) With Niraparib or Olaparib in Advanced Solid Tumors

Phase 1b/2 Study of ATR InhibiTor RP-3500 and PARP Inhibitor Combinations in Patients With Molecularly Selected Cancers (ATTACC)

Last checked: Nov 20, 2026Latest source record: Oct 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

156

Actual

Start

Jul 21, 2021

Primary completion

Nov 13, 2024

Study completion Nov 13, 2024

Sponsor

Lead sponsor
Repare TherapeuticsIndustry
Sponsor type
Industry
First posted
Jul 22, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this study is to assess the safety and tolerability of niraparib or olaparib in combination with RP-3500 (camonsertib), in patients with eligible advanced solid tumors, determine the maximum tolerated dose (MTD) of RP-3500 (camonsertib) in combination with niraparib or olaparib, examine pharmacokinetics (PK) and assess anti-tumor activity.

Conditions

  • Advanced Solid Tumor, Adult

Interventions

  • RP-3500 (camonsertib)Drug

    RP-3500 (camonsertib, ATR inhibitor) in combination with niraparib or olaparib (PARP inhibitors)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Determine the Safety and Tolerability of Niraparib or Olaparib in Combination With RP-3500 in Patients With Molecularly Selected Solid TumorsTime frame: Start of treatment to 30 days post last dose, up to 23.7 months
  2. Define the Recommended Phase 2 Dose (RP2D) of RP-3500 in Combination With Niraparib or Olaparib in Patients With Molecularly Selected Solid TumorsTime frame: During 21 days (one cycle) from the initiation of the study treatment

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • Participating Site #1018

    Phoenix, Arizona

  • Participating Site #1025

    San Francisco, California

  • Participating Site #1028

    Aurora, Colorado

  • Participating Site #1012

    New Haven, Connecticut

  • Participating Site #1017

    Jacksonville, Florida

  • Participating Site #1009

    Baltimore, Maryland

  • Participating Site #1015

    Ann Arbor, Michigan

  • Participating Site # 1016

    Rochester, Minnesota

  • Participating Site #1026

    New York, New York

  • Participating Site # 1008

    New York, New York

  • Participating Site #1029

    Eugene, Oregon

  • Participating Site # 1001

    Houston, Texas

  • Participating Site # 1013

    Salt Lake City, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.